The new USPTO director has embraced a recent Federal Circuit decision (Vanda v. Westward) that supports eligibility of patient-tailored therapies, pointing to a new pathway around the Supreme Court's decision in Mayo v. Prometheus. This favorable trend in eligibility coincides with the approval of two new immunotherapies by the FDA, which raises groundbreaking questions about the appropriate business models.
Join attorneys from Foley & Lardner LLP alongside seasoned corporate counsel as they discuss the future of biopharma method patents, options for business strategies, and how to align patent claim strategy for immunotherapy products with FDA labeling information. Topics include:
Featured Corporate Counsel Speakers Include:
Foley Speakers Include:
Foley & Lardner LLP will apply for CLE credit after the program, wherever applicable. Foley & Lardner LLP certifies that this activity has been approved for California MCLE credits by the State Bar of California in the amount of 1.0 General credit. Foley & Lardner LLP is a State Bar of California MCLE approved provider. Please note that participants must be in attendance on the date of the event; credit may not be obtained by viewing and/or listening to a program recording after the event. Certificates of attendance will be distributed to eligible participants approximately eight weeks after the program via email.
Important Information for New York Attorneys: This program is appropriate for experienced attorneys only.